Using modeling and simulation to predict drugs cardiotoxicity, moxifloxacin as an example. https://t.co/QGImd1iuHb @AAPSComms
RT @AAPSComms: #AAPSJ OPEN ACCESS! "Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac…
RT @AAPSComms: #AAPSJ OPEN ACCESS! "Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac…
#AAPSJ OPEN ACCESS! "Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin" #AAPS2018 https://t.co/J13RqKEPYA https://t.co/LJGOVayTLP
RT @ISSX: From @AAPSComms: Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Asse…
RT @ISSX: From @AAPSComms: Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Asse…
From @AAPSComms: Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin https://t.co/lVZw2ar3R8 https://t.co/ykk1Fv6ODE